TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18296121

Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 16135352

Group type: EXPERIMENTAL
Intervention: 1 CUN lateral to the femoral artery
Number of subjects: 62

Group type: COMPARATOR
Intervention: 1 cm lateral to the femoral artery
Number of subjects: 62

Group type: COMPARATOR
Intervention: 2 cm lateral to the femoral artery
Number of subjects: 62
Study: 12655261

Group type: EXPERIMENTAL
Intervention: Celecoxib 100 mg twice daily
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg twice daily
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 11185667

Group type: EXPERIMENTAL
Intervention: i.v. infusion of 10 mg/m2
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: i.v. infusion of 30 mg/m2
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: s.c. bolus of 20 mg/m2
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: i.v. administration
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: s.c. administration
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: s.c. dosing compared to i.v. dosing
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ribozyme administration
Number of subjects: 12
Study: 9264752

Group type: EXPERIMENTAL
Intervention: Improvement measures for hygiene and water supply, installation of latrines, and health education
Number of subjects: 0
Study: 1492863

Group type: EXPERIMENTAL
Intervention: Dihydroergocristine (DHEC) 6 mg tablet daily for four months
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 2871007

Group type: EXPERIMENTAL
Intervention: Propranolol (PROP, 160 mg/day)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Atenolol (ATEN, 100 mg/day)
Number of subjects: 22
Study: 28187041

Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted distal gastrectomy (LADG)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Open distal gastrectomy (ODG)
Number of subjects: 204
Study: 26767340

Group type: EXPERIMENTAL
Intervention: Multiple contests
Number of subjects: 1217

Group type: COMPARATOR
Intervention: Single contest
Number of subjects: 1217

Group type: EXPERIMENTAL
Intervention: Multiple contests with counseling
Number of subjects: 1217

Group type: COMPARATOR
Intervention: Single contest plus counseling
Number of subjects: 1217
Study: 24611528

Group type: EXPERIMENTAL
Intervention: Familias Unidas
Number of subjects: 242

Group type: COMPARATOR
Intervention: Community Practice
Number of subjects: 242
Study: 22219412

Group type: EXPERIMENTAL
Intervention: Complete revascularization by PCI
Number of subjects: 1766

Group type: COMPARATOR
Intervention: Incomplete revascularization by PCI
Number of subjects: 1766

Group type: COMPARATOR
Intervention: Incomplete revascularization by CABG
Number of subjects: 1766
Study: 20528963

Group type: EXPERIMENTAL
Intervention: Coronally Advanced Flap (CAF)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Semilunar Coronally Re-positioned Flap (SLCRF)
Number of subjects: 22
Study: 18610754

Group type: EXPERIMENTAL
Intervention: Low-dose IL-2
Number of subjects: 20

Group type: COMPARATOR
Intervention: MLT alone
Number of subjects: 20

Group type: COMPARATOR
Intervention: MLT plus 5-MTT
Number of subjects: 20
Study: 16061827

Group type: EXPERIMENTAL
Intervention: Antithyroid drugs
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (23 individuals)
Number of subjects: 43
Study: 12911137

Group type: EXPERIMENTAL
Intervention: Elderly subjects
Number of subjects: 30

Group type: COMPARATOR
Intervention: Young controls
Number of subjects: 30
Study: 9696964

Group type: EXPERIMENTAL
Intervention: Tiagabine (4 mg three times daily for 9 days)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Digoxin (0.5 mg twice a day for 1 day, then 0.25 mg once a day for 8 days)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Combined treatment of tiagabine and digoxin
Number of subjects: 13
Study: 7641777

Group type: EXPERIMENTAL
Intervention: Endoscopic oesophageal, gastric and duodenal biopsy
Number of subjects: 31
Study: 2830108

Group type: EXPERIMENTAL
Intervention: NaHCO3 (sodium bicarbonate)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (CaCO3)
Number of subjects: 6
Study: 29361433

Group type: EXPERIMENTAL
Intervention: Weekly text message intervention for 1 year
Number of subjects: 700

Group type: COMPARATOR
Intervention: Control group (no text messages)
Number of subjects: 700
Study: 26867930

Group type: EXPERIMENTAL
Intervention: Adaptive Copers (AC)
Number of subjects: 666

Group type: EXPERIMENTAL
Intervention: Interpersonally Distressed (ID)
Number of subjects: 666

Group type: EXPERIMENTAL
Intervention: Dysfunctional (DYS)
Number of subjects: 666
Study: 24723487

Group type: EXPERIMENTAL
Intervention: BEV/IRI (neo-adjuvant intravenous BEV, 10 mg/kg, and IRI, 125 mg/m², every 2 weeks for four cycles before RT; adjuvant BEV and IRI every 2 weeks for 6 months)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (concomitant oral TMZ, 75 mg/m²/day during RT, and 150-200 mg/m² for 5 days every 28 days for 6 months)
Number of subjects: 120
Study: 23245780

Group type: EXPERIMENTAL
Intervention: Food Friends: Get Movin' With Mighty Moves(®) program
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 201
Study: 21558573

Group type: EXPERIMENTAL
Intervention: Dark Chocolate (DC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 20
Study: 19560259

Group type: EXPERIMENTAL
Intervention: Open nephroureterectomy (ONU)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Laparoscopic nephroureterectomy (LNU)
Number of subjects: 80
Study: 16443447

Group type: EXPERIMENTAL
Intervention: Covariation information presented with natural language quantifiers in Experiment 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Covariation information presented with natural language quantifiers in Experiments 2-4
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attribution experiments using vignettes with covariation information
Number of subjects: 0
Study: 15233279

Group type: EXPERIMENTAL
Intervention: [11C]MP4A PET
Number of subjects: 13

Group type: COMPARATOR
Intervention: [123I]IMP SPECT
Number of subjects: 13
Study: 11378811

Group type: EXPERIMENTAL
Intervention: Vitamin C (150 mg), alpha-tocopherol (75 mg), beta-carotene (15 mg), selenium (101 microg), and calcium (1.6 g)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 116
Study: 9218294

Group type: EXPERIMENTAL
Intervention: Carmustine-loaded polymer (active treatment)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 32
Study: 8356525

Group type: EXPERIMENTAL
Intervention: Extracorporeal venovenous recirculation (EVR)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (existing therapy)
Number of subjects: 15
Study: 3902354

Group type: EXPERIMENTAL
Intervention: Enzyme-containing washing powder (alcalase)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: User test involving double blind wearing of vests washed with the product
Number of subjects: 255
Study: 31861114

Group type: COMPARATOR
Intervention: Educational program for the experimental group (EG) consisting of classes held on Saturday mornings (8:00 to 10:00 a.m.) for two months.
Number of subjects: 589

Group type: COMPARATOR
Intervention: Control group (CG) consisting of students from public and private schools who did not receive the educational intervention.
Number of subjects: 589
Study: 29688579

Group type: EXPERIMENTAL
Intervention: Avoralstat 500 mg
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Avoralstat 300 mg
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 26637834

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 9105

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 9105
Study: 24708300

Group type: EXPERIMENTAL
Intervention: Retroperitoneal laparoscopic pyelolithotomy (RLP)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Percutaneous nephrolithotomy (PCNL)
Number of subjects: 178
Study: 22820910

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Norclozapine
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Clozapine and Norclozapine
Number of subjects: 162
Study: 20470281

Group type: EXPERIMENTAL
Intervention: Low salt diet plus fosinopril (group 1)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Low salt diet plus fosinopril plus spironolactone (group 2)
Number of subjects: 85
Study: 18633043

Group type: EXPERIMENTAL
Intervention: Pudendal nerve block with 15 mL of ropivacaine 7.5 mg/mL
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 40
Study: 17723130

Group type: EXPERIMENTAL
Intervention: Daily rFVIIa prophylaxis with 90 microg kg(‐1) for 3 months
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Daily rFVIIa prophylaxis with 270 microg kg(‐1) for 3 months
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional on‐demand therapy
Number of subjects: 38
Study: 15115999

Group type: EXPERIMENTAL
Intervention: Endoscopic saphenectomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Open saphenectomy
Number of subjects: 40
Study: 11137071

Group type: EXPERIMENTAL
Intervention: Laparoscopic sterilization by Hulka clips
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Laparoscopic sterilization by Filshie clips
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Laparoscopic sterilization (both methods)
Number of subjects: 46
Study: 9361660

Group type: EXPERIMENTAL
Intervention: Multi-Frequency Bioelectrical Impedance Analysis (MFBIA)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Single MFBIA measurement
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Serial MFBIA measurements
Number of subjects: 53
Study: 1571118

Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate (900 mg) administered intravenously prior to surgery and continued every 8 hours for a total of 24 hours
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cefazolin sodium (2 g) administered intravenously prior to surgery and continued every 8 hours for a total of 24 hours
Number of subjects: 100
Study: 3911880

Group type: EXPERIMENTAL
Intervention: Amoxicillin‐clavulanic acid
Number of subjects: 104

Group type: COMPARATOR
Intervention: Co‐trimoxazole
Number of subjects: 104
Study: 29851070

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (0.02 g kg‐1 of an association of Lactobacillus acidophilus, Enterococcus faecium, Bifidobacterium thermophilum, and Bifidobacterium longum) with K2 Cr2 O7
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no probiotic, no K2 Cr2 O7)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: K2 Cr2 O7 at doses of 0.12 g kg‐1, 0.24 g kg‐1, and 0.36 g kg‐1
Number of subjects: 96
Study: 28400245

Group type: EXPERIMENTAL
Intervention: Cued recall task for original items
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Electrodermal responses during CIT
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Autonomic measures in CIT
Number of subjects: 75
Study: 25239014

Group type: EXPERIMENTAL
Intervention: 12-month multifactorial, interdisciplinary intervention
Number of subjects: 241

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 241
Study: 23540531

Group type: EXPERIMENTAL
Intervention: Classical alignment method
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Anatomical alignment method
Number of subjects: 117
Study: 21531737

Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Parenteral Nutrition (PN)
Number of subjects: 71
Study: 19660204

Group type: EXPERIMENTAL
Intervention: Flexible cystoscopy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Rigid cystoscopy
Number of subjects: 36
Study: 16043377

Group type: EXPERIMENTAL
Intervention: Dizziness Handicap Inventory (DHI) score for TBI group
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sensory Organization Test score for TBI group
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Biomechanical model kinematics for TBI group
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Relationship between DHI and posturography
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Motion of the COM and DHI score prediction
Number of subjects: 10
Study: 12399846

Group type: EXPERIMENTAL
Intervention: Ultracision (harmonic scissors) in group 1 (331 patients)
Number of subjects: 461

Group type: COMPARATOR
Intervention: Endo-loop in group 2 (130 patients)
Number of subjects: 461
Study: 12206010

Group type: COMPARATOR
Intervention: Fentanyl 5 micrograms.kg‐1 (Group F1)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Fentanyl 10 micrograms.kg‐1 (Group F2)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: URA 0.25 mg.kg‐1 plus fentanyl 5 micrograms.kg‐1 (Group U1)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: URA 0.5 mg.kg‐1 plus fentanyl 5 micrograms.kg‐1 (Group U2)
Number of subjects: 42
Study: 9108849

Group type: EXPERIMENTAL
Intervention: recombinant factor VIII (rFVIII)
Number of subjects: 10

Group type: COMPARATOR
Intervention: highly purified plasma‐derived factor VIII (pdFVIII)
Number of subjects: 10
Study: 1287904

Group type: EXPERIMENTAL
Intervention: Intravenous artesunate
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Artemisinin suppositories
Number of subjects: 79

Group type: COMPARATOR
Intervention: Intravenous quinine
Number of subjects: 79
Study: 3903734

Group type: EXPERIMENTAL
Intervention: Special Intervention (SI) program to reduce high blood pressure, elevated blood cholesterol, and/or cigarette smoking
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Special Intervention (SI) program
Number of subjects: 1000
Study: 31077773

Group type: EXPERIMENTAL
Intervention: Nostalgic food labels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Descriptive food labels
Number of subjects: 0
Study: 29630033

Group type: EXPERIMENTAL
Intervention: Interscalene block (ISB) with 20 mL of levobupivacaine 0.5% and epinephrine 5 μg/mL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Small-volume supraclavicular block (SCB) with 20 mL of levobupivacaine 0.5%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both ISB and SCB
Number of subjects: 0
Study: 27064369

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT) using the novel negative pressure device (NPD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard pressure ulcer (PU) wound dressing
Number of subjects: 0
Study: 24216257

Group type: EXPERIMENTAL
Intervention: Nutrition Education Program (NEP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Oral Supplementation (OS)
Number of subjects: 120
Study: 22767646

Group type: EXPERIMENTAL
Intervention: Group VC (VPA)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Group C (Control)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Group VM (VPA + MgSO4)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 55
Study: 20613550

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg 12 hours before PCI, with a further 40 mg preprocedure dose)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 17081523

Group type: EXPERIMENTAL
Intervention: Physiological oxygen concentration (5% O(2), 5% CO(2), and 90% N(2))
Number of subjects: 106

Group type: COMPARATOR
Intervention: Atmospheric oxygen concentration (5% CO(2) with the balance as air)
Number of subjects: 106
Study: 16054520

Group type: EXPERIMENTAL
Intervention: Probiotic treatment (Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3, B. bifidum MF 20/5, 5 x 10(7) cfu/tablet)
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Probiotic treatment
Number of subjects: 479

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 479
Study: 11199957

Group type: EXPERIMENTAL
Intervention: Bupropion sustained-release 300 mg/day
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 9531003

Group type: EXPERIMENTAL
Intervention: Prescribed intake of carbohydrate-electrolyte solution (6.9% Lucozade-Sport; sodium, 24 mmol l(‐1); potassium, 2.6 mmol l(‐1); calcium, 1.2 mmol l(‐1); osmolality, 300 mOsm kg(‐1))
Number of subjects: 7

Group type: COMPARATOR
Intervention: Ad libitum intake of carbohydrate-electrolyte solution
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Prescribed intake of carbohydrate-electrolyte solution
Number of subjects: 7
Study: 8270977

Group type: EXPERIMENTAL
Intervention: L-PAM plus BSO
Number of subjects: 28

Group type: COMPARATOR
Intervention: L-PAM alone
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: BSO
Number of subjects: 28
Study: 2481741

Group type: EXPERIMENTAL
Intervention: cyclobenzaprine (Flexeril)
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study: 53377

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 5

Group type: COMPARATOR
Intervention: Frusemide
Number of subjects: 5
Study: 31288820

Group type: EXPERIMENTAL
Intervention: liraglutide (1.8 mg/day)
Number of subjects: 47

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 47
Study: 28339462

Group type: EXPERIMENTAL
Intervention: Picaridin repellent
Number of subjects: 25000
Study: 25492378

Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sensor-augmented therapy
Number of subjects: 40
Study: 23453824

Group type: COMPARATOR
Intervention: Cold exposure (4°C) during recovery
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Temperate conditions (24°C) during recovery
Number of subjects: 20
Study: 21255828

Group type: COMPARATOR
Intervention: Amphotericin B (1 mg/kg infusion on alternate days for 30 days, total dose 15 mg/kg)
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B with miltefosine (single injection of 5 mg/kg liposomal amphotericin B and 7-day 50 mg oral miltefosine)
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B with paromomycin (single 10-day 11 mg/kg intramuscular paromomycin)
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Miltefosine and paromomycin (10 days each of miltefosine and paromomycin)
Number of subjects: 634
Study: 19229978

Group type: EXPERIMENTAL
Intervention: Pneumatic compression guided by mean artery pressure (MAP) after the procedure (Group A)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Standard pneumatic compression (15 cm³ of air in the device) (Group B)
Number of subjects: 351
Study: 16517515

Group type: EXPERIMENTAL
Intervention: Constraint‐Induced Movement Therapy (CIMT)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Traditional therapy (Control)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CIMT
Number of subjects: 8
Study: 12939591

Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2b plus ribavirin (PEG/R)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 10681486

Group type: EXPERIMENTAL
Intervention: triflusal 600 mg once daily for 35 days
Number of subjects: 2124

Group type: COMPARATOR
Intervention: aspirin 300 mg once daily for 35 days
Number of subjects: 2124
Study: 9018764

Group type: EXPERIMENTAL
Intervention: Loperamide oxide (4 mg twice daily for 1 week)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Loperamide oxide
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 7940002

Group type: EXPERIMENTAL
Intervention: Thoracoplasty
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fusion without thoracoplasty (Control)
Number of subjects: 50
Study: 3124721

Group type: EXPERIMENTAL
Intervention: Social skills training program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 30472404

Group type: EXPERIMENTAL
Intervention: WT combining with PSBL
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional training (CT)
Number of subjects: 20
Study: 29482543

Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment (NSPT) with immediate ultrasonic scaling, scaling and root planning, and subgingival 10% povidone iodine irrigation.
Number of subjects: 34

Group type: COMPARATOR
Intervention: Education only (control group).
Number of subjects: 34
Study: 28471557

Group type: EXPERIMENTAL
Intervention: 3D Quantitative Coronary Angiography (3D-QCA)
Number of subjects: 17

Group type: COMPARATOR
Intervention: 2D Quantitative Coronary Angiography (2D-QCA)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Bioresorbable Vascular Scaffold (BVS)
Number of subjects: 17
Study: 25446768

Group type: EXPERIMENTAL
Intervention: Thickened amino-acid formula (TAAF)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Reference amino-acid formula (RAAF)
Number of subjects: 86
Study: 22686269

Group type: EXPERIMENTAL
Intervention: Risk Reduction through Family Therapy (RRFT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 30
Study: 20046552

Group type: EXPERIMENTAL
Intervention: Manual treatment technique (4-minute pain-alleviating traction) at the most symptomatic zygopophyseal joint
Number of subjects: 126

Group type: COMPARATOR
Intervention: Manual treatment technique (4-minute pain-alleviating traction) 3 segments away from the concordant segment
Number of subjects: 126
Study: 17895349

Group type: EXPERIMENTAL
Intervention: BWSTT/UE‐EX
Number of subjects: 80

Group type: COMPARATOR
Intervention: CYCLE/UE‐EX
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: BWSTT groups (BWSTT/LE‐EX, BWSTT/CYCLE, BWSTT/UE‐EX)
Number of subjects: 80
Study: 15102867

Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg bid IV for 6 days with UFH on day 5 (n = 18)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) alone (n = 18)
Number of subjects: 36
Study: 12122123

Group type: EXPERIMENTAL
Intervention: Medical treatment for Charcot's arthropathy; specific intervention details not provided.
Number of subjects: 0
Study: 9457187

Group type: EXPERIMENTAL
Intervention: SH U 555 A (4 mumol Fe/kg)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: SH U 555 A (16 mumol Fe/kg)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: SH U 555 A (8 mumol Fe/kg)
Number of subjects: 169
Study: 7783654

Group type: EXPERIMENTAL
Intervention: Vasodilator administration (prazosin and hydralazine) alone or in combination with a beta‐blocker (propranolol)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Combined treatment (vasodilators + propranolol)
Number of subjects: 13